Literature DB >> 11999751

Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography.

F C Cheng1, Y F Ho, L C Hung, C F Chen, T H Tsai.   

Abstract

The disposition and biliary excretion of omeprazole was investigated following i.v. administration to rats at 10 mg/kg. We used a microdialysis technique coupled to a validated microbore HPLC system to monitor the levels of protein-unbound omeprazole in rat blood, brain and bile, constructing the relationship of the time course of the presence of omeprazole. Microdialysis probes were simultaneously inserted into the jugular vein toward right atrium, the brain striatum and the bile duct of the male Sprague-Dawley rats for biological fluid sampling after the administration of omeprazole (10 mg/kg) through the femoral vein. The concentration-response relationship from the present method indicated linearity (r2>0.995) over a concentration range of 0.01-50 microg/ml for omeprazole. Intra-assay and inter-assay precision and accuracy of omeprazole fell well within the predefined limits of acceptability. Following omeprazole administration, the blood-to-brain coefficient of distribution was 0.15, which was calculated as the area under the concentration versus time curve (AUC) in the brain divided by the AUC in blood (k=AUCbrain/AUCblood). The blood-to-bile coefficient of distribution (k=AUCbile/AUCblood) was 0.58. The decline of unbound omeprazole in the brain striatum, blood and bile fluid suggests that there was rapid exchange and equilibration between the compartments of the peripheral and central nervous systems. In addition, the results indicated that omeprazole was able to penetrate the blood-brain barrier and undergo hepatobiliary excretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999751     DOI: 10.1016/s0021-9673(01)01225-0

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  10 in total

1.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia.

Authors:  Felicia C Goldstein; Kyle Steenland; Liping Zhao; Whitney Wharton; Allan I Levey; Ihab Hajjar
Journal:  J Am Geriatr Soc       Date:  2017-06-07       Impact factor: 5.562

3.  Risk of dementia in elderly patients with the use of proton pump inhibitors.

Authors:  Britta Haenisch; Klaus von Holt; Birgitt Wiese; Jana Prokein; Carolin Lange; Annette Ernst; Christian Brettschneider; Hans-Helmut König; Jochen Werle; Siegfried Weyerer; Melanie Luppa; Steffi G Riedel-Heller; Angela Fuchs; Michael Pentzek; Dagmar Weeg; Horst Bickel; Karl Broich; Frank Jessen; Wolfgang Maier; Martin Scherer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-24       Impact factor: 5.270

4.  A recursive-partitioning model for blood-brain barrier permeation.

Authors:  S R Mente; F Lombardo
Journal:  J Comput Aided Mol Des       Date:  2005-12-06       Impact factor: 3.686

5.  Associations between proton pump inhibitors and Alzheimer's disease: a nested case-control study using a Korean nationwide health screening cohort.

Authors:  Hyo Geun Choi; Joo-Hee Kim; Ji Hee Kim; Eun Soo Kim; Ha Young Park; Kyueng-Whan Min; Mi Jung Kwon
Journal:  Alzheimers Res Ther       Date:  2022-07-01       Impact factor: 8.823

6.  Elevated anxiety, hypoactivity, memory deficits, decreases of brain serotonin and 5-HT-1A receptors expression in rats treated with omeprazole.

Authors:  Sadia Basharat Ali; Khalid Mahmood; Raheel Saeed; Tabinda Salman; Muhammad Iqbal Choudhary; Darakhshan Jabeen Haleem
Journal:  Toxicol Res       Date:  2020-09-17

Review 7.  Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis.

Authors:  Sangita Biswas; Stephen H Benedict; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2012-06-07       Impact factor: 8.775

8.  Regular proton pump inhibitor use and incident dementia: population-based cohort study.

Authors:  Peidong Zhang; Zhihao Li; Peiliang Chen; Ao Zhang; Yu Zeng; Xiru Zhang; Qingmei Huang; Dan Liu; Songtao Qi; Chen Mao
Journal:  BMC Med       Date:  2022-09-01       Impact factor: 11.150

Review 9.  Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences.

Authors:  Gloria Ortiz-Guerrero; Diana Amador-Muñoz; Carlos Alberto Calderón-Ospina; Daniel López-Fuentes; Mauricio Orlando Nava Mesa
Journal:  Neural Plast       Date:  2018-03-21       Impact factor: 3.599

10.  The Janus-like Association between Proton Pump Inhibitors and Dementia.

Authors:  Anna Papazoglou; Muhammad I Arshaad; Christina Henseler; Johanna Daubner; Karl Broich; Britta Haenisch; Marco Weiergräber
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.